Of 1008 randomized patients , the odds of experiencing grade 3 ATE were significantly greater in those who received bevacizumab compared with those who received placebo ( odds ratio , 2.79 ; P = .02 ) , whereas an opposite trend was noted for grade 3 VTE ( odds ratio , 0.60 ; P = .08 ) .